Product Program year 2025 Source: CMS Open Payments

Onyda XR

Drug Adhd

NDC 24478-148-02

Open in the dashboard

General payments

$585,834

3,560 payments

Research payments

$0

0 payments

Through program year 2025, $585,834 in general payments and $0 in research payments were reported against Onyda XR (Adhd).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $569,877 2,870
2024 General $15,957 690

Breakdown

Who paid General payments · program years 2024–2025
  1. Tris Pharma Inc $585,834 3,560 payments
Top recipients General payments · program year 2025
  1. Ann Childress Child & Adolescent Psychiatry · Las Vegas, NV $482,400 85% · 1 payment
  2. Rakesh Jain Psychiatry · Lake Jackson, TX $11,250 2% · 4 payments
  3. George Bright Adolescent Medicine · Midlothian, VA $5,724 1% · 12 payments
  4. Lawrence Ginsberg Psychiatry · Houston, TX $5,000 <1% · 1 payment
  5. Gregory Mattingley Psychiatry · Saint Charles, MO $3,500 <1% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Child & Adolescent Psychiatry Psychiatry & Neurology $485,732 85% · 68 practitioners
  2. Psychiatry Psychiatry & Neurology $28,150 5% · 172 practitioners
  3. Pediatrics $14,652 3% · 530 practitioners
  4. Nurse Practitioner, Psychiatric/Mental Health Nurse Practitioner $11,344 2% · 332 practitioners
  5. Adolescent Medicine Family Medicine $5,742 1% · 2 practitioners

The top 5 of 43 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Nevada $482,557 85% · 4 recipients
  2. Texas $32,716 6% · 470 recipients
  3. Florida $11,275 2% · 289 recipients
  4. Virginia $6,317 1% · 22 recipients
  5. Georgia $6,152 1% · 158 recipients

The top 5 of 42 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

3,560 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record